Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist

A receptor agonist and ophthalmic preparation technology, applied in the field of ophthalmic preparations, can solve problems such as no description, no description of inhibiting side effects, etc.

Inactive Publication Date: 2006-08-16
SENJU PHARMA CO LTD
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the report does not describe a percutaneous absorption type formulation that promotes tear secretion, nor does it describe suppression of side effects such as miosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
  • Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
  • Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Ointment Containing Pilocarpine Hydrochloride

[0102] Pilocarpine Hydrochloride 0.3g

[0103] (produced by Nacalai Tesque Inc.)

[0104] Isopropyl myristate 1.2g

[0105] White petrolatum 1.5g

[0106] Total 3g

[0107] According to the above formulation, white petrolatum and isopropyl myristate were thoroughly mixed, pilocarpine hydrochloride was added to the mixed ointment base and fully kneaded to obtain an ointment containing pilocarpine hydrochloride.

Embodiment 2

[0109] Gel Containing Pilocarpine Hydrochloride

[0110] Pilocarpine Hydrochloride 0.3g

[0111] (produced by Nacalai Tesque Inc.)

[0112] Isopropyl myristate 1.2g

[0113] 2% carboxyvinyl polymer gel 1.5

[0114] Total 3g

[0115] Carboxyvinyl polymer (1 g) was added in a small proportion to purified water (49 mL), and after sufficient dispersion and swelling, 8N-NaOH (1 mL) was added to neutralize the mixture to obtain a transparent 2% carboxyvinyl base polymer gel matrix. Isopropyl myristate was added to the gel base (1.5 g) and the mixture was mixed. Pilocarpine hydrochloride was added and the mixture was well kneaded to obtain a gel containing pilocarpine hydrochloride.

Embodiment 3

[0117] Paste containing pilocarpine hydrochloride

[0118] Pilocarpine Hydrochloride 0.3g

[0119] (produced by Nacalai Tesque Inc.)

[0120] Sodium polyacrylate 0.45g

[0121] Glycerin 0.3g

[0122] Peppermint Oil 0.01g

[0123] Appropriate amount of purified water

[0124] Total 3g

[0125] Sodium polyacrylate and glycerin are thoroughly mixed with purified water to obtain an aqueous plaster. Separately, peppermint oil and pilocarpine hydrochloride were added and the mixture was well kneaded. The paste containing pilocarpine hydrochloride was obtained by molding the plaster mix on a support (polyester non-woven fabric, etc.) by flattening and applying a release liner.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

In order to make available an ophthalmic percutaneously absorbed preparation that is capable of maintaining a therapeutically effective concentration of muscarinic receptor agonist for facilitating lacrimation and that realizes reduction of side effects such as pupillary constriction, and in order to make available a method of facilitating lacrimation through administration of an ophthalmic percutaneously absorbed preparation containing a muscarinic receptor agonist to a surface of eyelid skin, there is provided an ophthalmic percutaneously absorbed preparation comprising a muscarinic receptor agonist that is capable of facilitating lacrimation through administration to a surface of eyelid skin and that realizes reduction of side effects such as pupillary constriction.

Description

technical field [0001] The present invention relates to a percutaneous absorption type ophthalmic preparation comprising a muscarinic receptor agonist for promoting tear secretion by application to the skin surface of the eyelid. Furthermore, the present invention relates to a method for promoting tear secretion by applying a percutaneous absorption type ophthalmic preparation comprising a muscarinic receptor agonist to the skin surface of the eyelid. Background technique [0002] Dry eye is a pathology caused by decreased tear secretion and changes in tear composition and can lead to erosion of the corneal and conjunctival epithelium, foreign body sensation, etc. Dry eye includes, for example, caused by eye diseases such as Sjogren's syndrome, Stevens-Johnson syndrome, blepharitis, meibomitis, etc., by VDT (Visual Display Terminal (Visual Display Terminal)) surgery, application Caused by contact lenses, etc. As a method of preventing or treating dry eye, supplementation o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K9/06A61K9/70A61K31/4178A61K31/439A61K47/14A61P25/02A61P27/02A61K9/00
CPCA61K9/0048A61K31/439A61K31/4178A61P25/02A61P27/02A61P27/04
Inventor 礒胁明治大鸟聪
Owner SENJU PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com